Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in alvetex®
16 / 11 / 2011
Sedgefield, UK. November 2011. Reinnervate (Sedgefield, UK) and Mirus Bio (Madison, USA) today announced a commercial agreement to launch a new range of products for the transfection of cells cultured in 3D.
Under the agreement, Mirus will produce and sell kits combining TransIT®-3D Transfection Reagent, alvetex® 3D cell culture plates and detailed protocols for achieving transfection of selected cell lines growing in 3D.
The kits will enable scientists to evaluate the growth of cells in 3D, allowing more native cell structure, morphology and functionality before transfection with a specific gene of interest with a robust transfection protocol.
“Scientists are increasingly looking for in-vitro cell-based assays that better mimic and predict complex biological processes”, commented Richard Rowling, Commercial Director at Reinnervate. “We believe the 3D Transfection System will be of broad appeal for cell biologists seeking to improve their research capabilities beyond the limitations of mono-layer culture. We are delighted to be collaborating with Mirus to help make 3D cell culture a more routine laboratory technique”.
Scott Hayes (R&D Director of Mirus Bio) added “Cell based research is actively moving towards cellular models, such as 3D cell culture, that more accurately represent intact tissue,” said Scott Hayes, Vice President of Scientific Operations at Mirus Bio, LLC. “With the introduction of the TransIT®-3D Transfection Reagent, Mirus addresses an unmet need for efficient delivery of nucleic acids to cells established and propagated in a 3D cell culture environment. By combining the TransIT®-3D Transfection Reagent with the innovative scaffold structure of alvetex® plates from Reinnervate, researchers will have access to a cell culture model that is more biologically relevant than routine 2D culture and amenable to easy and high-efficiency transfection.”
Financial terms were not disclosed.
Alvetex® is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in the laboratory, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated alvetex® with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex® has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep petri dish. These formats provide researchers with an exceptional degree of versatility in how they choose to construct different 3D cell culture models. Through enabling alternative applications, such as long-term 3D cell culture over several weeks, 3D cell growth at air/liquid interface and 3D cell growth with different media constituents, to be performed simply and routinely, reinnervate continues to make genuine 3D cell culture a reality for researchers today.
Alvetex® was named among the winners of The Scientist magazine’s “Top 10 Life Science Innovations of 2010” and was selected among the most technologically significant of 2010 in the 49th Annual R&D100 Awards.
See the company video - www.reinnervate.com/company-video
About Mirus Bio
The Transfection Experts. More than 15 years of gene delivery expertise.
The TransIT®-3D Transfection Reagent complements Mirus Bio’s transfection offerings which include TransIT®-LT1 Broad Spectrum Transfection Reagent, TransIT-TKO® siRNA Transfection Reagent and a multi-platform, non-chemical alternative: Ingenio® Electroporation Kits.
Mirus pioneered scientific breakthroughs in non-viral gene delivery. These advances established our products as industry leading transfection reagents. At Mirus, we continue to expand on our expertise in nucleic acid delivery research and products to better serve you.
For further information, please contact
Ashley Cooper, Chief Executive Officer
+44 (0)1740 625266
+44 (0) 1489 557672
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate’s core technology is alvetex®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex® provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Cells grown using alvetex form complex 3D tissue cultures which more closely mimic normal in-vivo cell growth and the formation of tissues in the body than conventional techniques. The use of alvetex-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.
Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of alvetex in a large number of cell types and applications. Alvetex® has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep well petri dish.
Reinnervate continues to develop its technology for use in the 3D cell culture. During 2012 Reinnervate will deliver further innovative products to help researchers improve the growth and function of their cultured cells
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
Reinnervate Ltd to be present at the Beatson Cancer…
Reinnervate Ltd will be present at the Beatson Cancer Conference in Glasgow on 10th July 2013. Representatives from Reinnervate will be on hand to present and discus the…> read more
Reinnervate and Promega to present 3D cell culture…
Reinnervate Ltd and Promega Corp. will present a series of joint seminars on the US West coast in June 2013. Seminars will take place in San Diego (Tuesday 11th June), Seattle (Wednesday…> read more
3rd Cell-Based Assays event 18th - 19th March 2013,…
Professor Stefan Przyborski, founder and Chief Scientific Officer of Reinnervate will present on Alvetex Technology That Enables Routine 3D Cell Culture, at 2pm on 18th March at ULU University of…> read more
ELRIG Research & Innovation 19th March 2013
Richard Rowling Commercial Director of Reinnervate will present on Target-based drug activity and post-translational and transcriptional analysis using ex vivo Alvetex®Scaffold three-dimensional…> read more
Reinnervate to Exhibit at the American Association…
Reinnervate will exhibit at the American Association for Cancer Research, Annual Meeting, 6th – 10th April, at the Walter E, Washington Convention Centre, Washington, DC.
3D cell culture firm Reinnervate and specialist Oncology…
3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement. Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating…> read more
3D cell culture firm Reinnervate announce the release…
Sedgefield, UK. November 2012 - Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has launched and commenced shipments of Alvetex®Scaffold 96 well plates to customers.
> read more
Reinnervate to Exhibit at the American Society for…
Reinnervate are exhibiting at the American Society for Cell Biology Annual Conference to be held in San Francisco, California. We would be delighted to welcome you at booth 1017-1019 to discuss our…> read more
New evidence-based 3D cell culture web portal launched…
Sedgefield, UK. October 2012 – Reinnervate Ltd, the developers of Alvetex®Scaffold for 3D cell culture, today announced the launch of a new 3D cell culture portal for scientists in the life…> read more
Medicyte GmbH and Reinnervate Ltd to collaborate on…
Heidelberg, Germany and Sedgefield, UK. 9th July 2012 - Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte…> read more
Top award for 3D cell culture pioneer, Stefan Przyborski,…
Sedgefield, UK. June 2012 – Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd has been recognised with a top award from the Royal Society of Chemistry.
The Rita and John…
Reinnervate and Tecan to develop automated 3D cell…
Sedgefield, UK and Männedorf, Switzerland. 7 June 2012. Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture,…> read more
Reinnervate Ltd and Roslin Cellab announce plans to…
Sedgefield, UK. April 2012. Reinnervate Ltd and Roslin Cellab, two leading UK companies in the fields of 3D cell culture and stem cell biology, today announced that they will join…> read more
Reinnervate Ltd announce Kirkstall Ltd collaboration
Reinnervate (inventors of alvetex®scaffold) and Kirkstall (developers of the Quasi-Vivo® system) today announced that they will collaborate to bring next generation three…> read more
Reinnervate and Mirus Bio announce collaboration with…
Sedgefield, UK. November 2011. Reinnervate (Sedgefield, UK) and Mirus Bio (Madison, USA) today announced a commercial agreement to launch a new range of products for the transfection…> read more
Reinnervate Expands its Distribution Network for alvetex®…
Sedgefield, UK. October 2011. Reinnervate, the emerging global leader in the rapidly growing 3D cell culture market, is delighted to announce it has signed agreements with seven new European distributors…> read more
alvetex® voted one of most technologically…
Sedgefield, UK. 23rd June 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that alvetex®, its breakthrough…> read more
Reinnervate partners with AMS Biotechnology (Europe)…
Sedgefield, UK. 31 May 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that it is partnering with AMS Biotechnology…> read more
SelectScience TV interviews Ashley Cooper of Reinnervate…
Ashley Cooper discusses the launch of the second wave of Alvetex® products for 3D cell culture with SelectScience TV. To watch the interview and learn how Alvetex® products…> read more
Reinnervate to launch alvetex® in the…
Sedgefield, UK. 11th March 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce the upcoming US launch of alvetex®…> read more
Reinnervate enhances commercial and product development…
Sedgefield, UK. 8th March 2011. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, is delighted to announce the appointments of Richard Rowling as Commercial Director…> read more
Alvetex® named in the top ten life…
Sedgefield, UK. 1st December 2010 Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that alvetex®, its breakthrough…> read more
Reinnervate partners with LGC for global distribution…
Sedgefield, UK. 29th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that it is partnering with LGC Standards…> read more
Reinnervate launches alvetex®, a breakthrough…
Sedgefield, UK. 22nd November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is very pleased to announce today the first commercial launch…> read more
Reinnervate gears up for the launch of alvetex®…
Sedgefield, UK. 18th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced the appointment of Classic Industries Europe for…> read more
Reinnervate completes expansion into new purpose-built…
Sedgefield, UK. 16th November 2010 Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research…> read more
Reinnervate to speak at the Cell-based Assays Conference…
reinnervate is pleased to announce that Professor Stefan Przyborski, reinnervate’s founder and Chief Scientific Officer, will be presenting at the third annual conference on Cell-based Assays…> read more
Reinnervate launches new website with interactive…
Sedgefield, UK. 7th October 2010 reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced the launch of its new, fully interactive website…> read more
Reinnervate wins Chemistry Innovation / EPSRC Industrial…
Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold…> read more
Reinnervate secures £1.8 million of investment to…
Sedgefield, UK. 27th May 2010. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, today announced that it had successfully raised £1.8 million in new equity…> read more